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We report the selection and amplification of the broad-host-range Salmonella phage phi PVP-SE1 in an
alternative nonpathogenic host. The lytic spectrum and the phage DNA restriction profile were not modified
upon replication in Escherichia coli Bl21, suggesting the possibility of producing this phage in a nonpathogenic
host, contributing to the safety and easier approval of a product based on this Salmonella biocontrol agent.
Salmonella enterica has long been recognized as an impor-
tant zoonotic pathogen of economic significance in animals
and humans and remains the primary cause of reported food
poisonings worldwide, with massive outbreaks occurring in re-
cent years (9, 14, 33). The serovars most commonly reported in
human infections in the European Union (EU) and the United
States have been Enteritidis and Typhimurium, comprising,
respectively, 76% and 14% of the cases in the EU (14, 15, 27).
Therefore, controlling Salmonella infections has become an
important goal for the poultry industry, the most common
source of Salmonella Enteritidis infections (3, 7, 14, 33).
The use and misuse of antimicrobials in both humans and
animals have given rise to the emergence of infectious bacteria
displaying resistance toward many, and in some cases all, ef-
fective antimicrobials (2, 14, 33). Thus, the development of
alternatives to chemotherapy is imperative and a critical pri-
ority. The use of (bacterio)phages, viruses that specifically in-
fect and lyse bacteria, as a therapeutic agent (phage therapy) is
one possible option for controlling pathogenic bacteria. Phages
have already been tested as biocontrol agents for salmonellae
and other pathogens in humans and animals, with success
showing advantages over antibiotics (4, 23, 25, 29–31). How-
ever, due to the high specificity of phages, they often can only
be produced in their natural hosts (7, 35), which, in the case of
pathogenic hosts, turns out to be problematic due to the re-
lease of cell debris and large quantities of both endotoxins and
exotoxins and the presence of live cells that are then found in
the crude phage lysate (10, 24, 29, 32).
The use of a nonpathogenic host in the production process
would eliminate the risk of accidentally administering a patho-
gen (6, 7, 24). Consequently, it would greatly simplify the
purification process, with a consequent reduction in cost and
would furthermore increase the safety of phage preparations,
leading to easy and faster approval of phage products. Never-
theless, this tends to be a difficult approach since multivalent
phages are rare (6, 7, 19, 29).
The aims of this work were to select and characterize a
Salmonella phage with a broad lytic spectrum and study the
possibility of producing it in a nonpathogenic Escherichia coli
strain.
Phage lytic spectrum. Thirteen Salmonella phages isolated
in the scope of the European project Phagevet-P were used,
and the three with the broadest host ranges are presented in
Table 1 along with their hosts. Also, broad-host-range Salmo-
nella phage Felix-O1, acquired from the Profos AG collection
(Regensburg, Germany), was used. To determine the phages’
lytic spectra, drops (10 l) of serial dilutions of the different
phage suspensions were added to bacterial lawns (Tables 1 and
2). LB broth, Miller (Sigma-Aldrich Inc., St. Louis, MO), was
the medium used, and it was prepared according to the man-
ufacturer’s instructions. Agar plates and soft agar were pre-
pared by adding, respectively, 1.2% and 0.6% agar (Appli-
chem, Darmstadt, Germany) to the LB broth. The plates were
incubated overnight at 37°C, and the lytic activity was checked
for the formation of clear areas and phage plaque formation
on the bacterial lawns. Thirty-eight bacterial strains were used
(Tables 1 and 2). The strains in Table 1 belong to serovar
Enteritidis (detailed information about these strains can be
found in reference 28), and two E. coli strains (N5-bovine and
N9-porcine) were also isolated (Table 2). The remaining
strains were from the NCTC (National Collection of Type
Cultures), ATCC (American Type Culture Collection), SGSC
(Salmonella Genetic Stock Centre), and CECT (Coleccio´n Es-
pan˜ola de Cultivos Tipo) type culture collections. At least two
salmonellae from each subspecies were used. The two well-
known E. coli strains BL21 [BL21-Gold(DE3), purchased from
Stratagene] and K-12 were also used to test the ability of the
phage to be amplified in an alternative host.
Phage phi PVP-SE1 showed the broadest lytic spectrum.
Besides being able to lyse almost all Salmonella strains (of all
Salmonella subtypes except IIIa), it was also able to infect E.
coli BL21 and K-12, and thus, phi PVP-SE1 can be considered
a multivalent phage. Moreover, this phage was able to infect
more strains than Felix-O1 (Table 1), which is known for its
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wide lytic spectrum among salmonellae. This result supports
the evidence that this newly isolated phage has a very broad
lytic spectrum, and therefore it is an interesting candidate for
use in phage therapy. The ability of phi PVP-SE1 to infect the
two E. coli strains (BL21 and K-12) and the production of very
clear lysis areas on lawns of BL21 encourage the selection of
this nonpathogenic strain for production of the phage.
Phage morphology. The morphology of phage phi PVP-SE1
was analyzed using transmission electron microscopy (TEM)
(Fig. 1). Phage particles were sediment at 25,000  g for 60
min using a Beckman (Palo Alto, CA) J2-21 centrifuge with a
JA 18.1 fixed-angle rotor. Phages were washed twice in 0.1 M
ammonium acetate (pH 7.0), deposited on copper grids pro-
vided with carbon-coated Formvar films, stained with 2% po-
tassium phosphotungstate (pH 7.2), and examined in a Philips
EM 300 electron microscope (by H.-W. Ackermann, Laval
University, Quebec, Canada). Morphologically, this phage be-
longs to the Myoviridae family, is characterized by its contrac-
tile tail, and resembles typical O1-like phages (Fig. 1) (H.-W.
Ackermann, Universite´ Laval, Quebec, Canada, personal com-
munication). However, this phage has a head size of 84 nm and
a tail of 120 by 18 nm, which are considerably larger than those
of typical O1-like phages (72 nm, 113 by 17 nm) (1, 21, 34).
Phage production in a nonpathogenic host. To assess
whether the phage maintains its lytic profile when grown in an
alternative nonpathogenic host, the phage was produced for six
generations in E. coli BL21. Phages were amplified by plate
lysis as described by Sambrook and Russell (26). Generation
one (G1) of phage phi PVP-SE1 in E. coli BL21 was produced
using the phage stock suspension obtained for phi PVP-SE1 in
Salmonella S1400/94 (G0). This production was then used as a
stock suspension to produce G2 of phage phi PVP-SE1 in E.
coli BL21. G3 to G6 were obtained using the same procedure;
i.e., each generation was obtained using phages from the pre-
vious generation. It was observed that the lytic spectrum of the
phage was maintained from G0 until G6. This indicates that
replication of the phage in this alternative host will not narrow
its lytic spectrum. Taking into account these characteristics, a
broad lytic spectrum and the ability to be amplified in a non-
pathogenic strain without modification of its lytic spectrum,
phage phi PVP-SE1 was further characterized and G6 was
compared with G0.
Phage infection parameters. The phage infection parame-
ters of G0 and G6 were determined through single-step growth
curve experiments carried out at 37°C in LB medium as de-
scribed by Sambrook and Russell (26), using an overnight
preinoculum of the bacteria in the same medium. The exper-
iments were done in duplicate and repeated on two different
occasions. The values of the parameters were determined by
fitting the experimental data to a four-parameter sigmoid curve
using least-squares fitting. Figure 2 shows the increase in phage
TABLE 1. Comparison of the lytic spectra of isolated Salmonella
phages and phage Felix-O1 against poultry Salmonella isolatesa
Salmonella Enteritidis
strain
Lysis by phage (host):
phi PVP-SE1
(S1400/94)
phi PVP-SE2
(821)
phi PVP-SE3
(869) Felix-O1
AL855    NT
EX2  L  
S1400/94    
269    
546    
629B    
657  L L 
821    
855  L  
869    
905    
932    
9510.85  L L 
a , absence of a phage halo and phage plaques; , presence of a phage halo
and phage plaques; L (lysis from without), presence of a phage halo and absence
of phage plaques; NT, not tested.
TABLE 2. Lytic spectra of isolated Salmonella phages against
different Salmonella subtypes and bacteria
other than salmonellaea
Strain
Lysis by phage:
phi
PVP-SE1
phi
PVP-SE2
phi
PVP-SE3
Salmonella Typhimurium NCTC
12416 subsp. I
  
Salmonella NCTC 13349 subsp. I   
Salmonella sp. strain SGSC 3047
subsp. II
  
Salmonella sp. strain SGSC 3039
subsp. II
  
Salmonella Arizonae SGSC 3063
subsp. IIIa
L  
Salmonella Arizonae 83 (isolate)
subsp. IIIa
  
Salmonella sp. strain SGSC 3069
subsp. IIIb
  
Salmonella sp. strain SGSC 3068
subsp. IIIb
  
Salmonella sp. strain SGSC 3086
subsp. IV
L  
Salmonella sp. strain SGSC 3074
subsp. IV
  
Salmonella Bongori SGSC 3103
subsp. V
  
Salmonella Bongori SGSC 3100
subsp. V
  
Salmonella sp. strain SGSC 3118
subsp. VI
  
Salmonella sp. strain SGSC 3116
subsp. VI
  
Salmonella sp. strain SGSC 3121
subsp. VII
  
Salmonella sp. strain SGSC 3120
subsp. VII
  
Escherichia coli N9 L  
Escherichia coli N5 L  
Escherichia coli CECT 434
(ATCC 25922)
L  
Escherichia coli BL21   
Escherichia coli K-12   
Enterobacter amnigenus CECT
4078 (ATCC 33072)
L  
Enterobacter aerogenes CECT
684 (ATCC 13048)
  
Klebsiella pneumoniae 11296   
Shigella flexneri ATCC 12022   
a , absence of a phage halo and phage plaques; , presence of a phage halo
and phage plaques; L (lysis from without), presence of a phage halo and absence
of phage plaques; NT, not tested.
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concentration through time of G0 in S1400/94 and G6 in BL21.
Three phage infection parameters were determined, i.e., burst
sizes of 102 and 28 phages per infected host cell; rise periods of
11 and 21 min, respectively, for G0 and G6; and the same
latency period of 19 min. The differences between the burst
sizes and rise periods are attributed to the use of a different
host to replicate the phage once it was determined that the
phage had not suffered any modification, and the only variable
in the experiments (besides the phage generation) was the host
used. To corroborate this fact, we repeated the experiment
using phage from G0 and E. coli BL21 as the host and obtained
the same result. The increased safety, and consequently the
lower cost of producing a safer phage product, obtained when
producing phi PVP-SE1 in a nonpathogenic host can overcome
the disadvantages of a smaller burst size and a longer rise
period.
Phage restriction fragment length polymorphism (RFLP).
Further characterization of phage phi PVP-SE1 was carried
out by determining the restriction profile of phage DNA (Fig.
3). Phage DNA was extracted using the Wizard DNA
Clean-Up System from Promega Corporation (Madison, WI)
and digested with HindIII and EcoRV from Sigma-Aldrich
Inc. (St. Louis, MO) according to the manufacturer’s instruc-
tions. Fragments were separated on a 1% agarose (Bio-Rad
Laboratories Inc., Hercules, CA) gel at 70 V for 3 h (20 V for
16 h when DNA was digested with HindIII) and stained with
ethidium bromide (1 g/ml; Bio-Rad Laboratories Inc., Her-
cules, CA). Based on the restriction profile, it was possible to
estimate a genome size of approximately 146 kb. In order to
assess if replication of the phage in E. coli BL21 could cause
significant mutations or modifications in the phage DNA, the
DNA from G6 was extracted and digested with EcoRV, which
produces a great number of bands with different sizes. Com-
parison of its restriction profile with that of G0 (phage grown
in its natural host, Salmonella S1400/94) showed no difference.
Influence of the last host on the phage phenotype. The
genotype of the host in which a virus reproduces affects the
phenotype of the newly formed virus progeny (22). In contrast
to mutation, antagonist pleiotropy may be applied simulta-
neously to almost all of the members of a developing phage
population and generally is determined only by the nature of
the last host in which the phage was replicated, being indepen-
dent of the previous phage history (13). As a consequence of
this ubiquitous phenomenon, the growth and adaptation of the
virus to the new host will lead to the achievement of a new
stock that may be divergent from the original (11, 12). Taking
into account this science-based knowledge, it would be ex-
pected that the replication of a phage in a different host would
lead to progeny with different characteristics. In fact, the phe-
nomenon of host-controlled variation has already been re-
ported for phages and is usually produced in a few growth
cycles; in some cases, the phenotypic change is evident right
after a single growth step where phages lose their ability to
FIG. 1. TEM of phage phi PVP-SE1.
FIG. 2. Sim-fitted one-step growth curve of phage phi PVP-SE1 G0
in Salmonella S1400/94 and phi PVP-SE1 G6 in E. coli BL21. Exp,
experimental values (average values  standard deviations).
FIG. 3. Restriction profile of phage phi PVP-SE1 DNA. (a) phi
PVP-SE1 G0 DNA digested with HindIII. (b) phi PVP-SE1 DNA (G0
and G6) digested with EcoRV. Lane M (marker) is a HindIII digest of
lambda DNA.
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growth and lyse their original host (5, 8, 11, 13). Therefore, the
use of a nonpathogenic host to produce phages for therapeutic
purposes could be compromised by induced changes in the
phage lytic spectrum.
In this study, the lytic activity of the phage after its replica-
tion in the nonpathogenic strain E. coli BL21 (G1 to G6)
showed an efficiency equal to that of phi PVP-SE1 produced in
Salmonella (G0), and thus, no host-induced modification of the
phage or restriction by the pathogenic target bacteria occurred;
i.e., there was no increase in the specificity of the phage to that
strain with consequent narrowing of the host range. Therefore,
in this case, it is expected that there will be no risk of treatment
failure, in contrast to what happened in the past when phages
were produced in laboratory strains and then used in therapy
(36). Moreover, this work shows that the production of Salmo-
nella phage phi PVP-SE1 in nonpathogenic E. coli BL21 main-
tained its ability to lyse Salmonella strains and did not induce
DNA modifications visible by RFLP.
Importance of broad-host-range phages. The aims of this
work were to select and characterize a phage with a broad host
range of Salmonella strains and to investigate the possibility of
producing this phage in a nonpathogenic strain. The highly
specialized nature of phages and the uncommon existence in
nature of broad-host-range phages (with a host range over
species borders) make the isolation of such phages a rare
situation. In particular, the narrow host specificity of Salmo-
nella phages and the relatively large number of pathogenic
Salmonella strains exacerbate this difficulty (16, 29). The
phages used in this study might thus have added value in phage
therapy since all of them present a broad host range among
Salmonella strains. Of particular interest is phage phi PVP-
SE1, which was able to lyse almost all of the Salmonella strains
used in this work and also bacteria other than salmonellae, e.g.,
the nonpathogenic strain E. coli BL21. It is believed that the
broader the host range of a phage, the higher the probability of
success in phage therapy and also of finding alternative hosts in
which to reproduce the phage (18).
Comparing the lytic spectra of this phage and the well-
known phage Felix-O1 (a virulent phage originally isolated by
Felix and Callow in 1943 [20]) among the isolates tested, it was
observed that phi PVP-SE1 presents a broader host range than
Felix-O1. Felix-O1 is used routinely as a diagnostic tool in the
identification of salmonellae due to its ability to lyse up to
99.5% of Salmonella strains (17). Thus, like Felix-O1, newly
isolated phage phi PVP-SE1 can also be an excellent diagnostic
tool.
Concluding remarks. This work reports the selection and
characterization of phi PVP-SE1, a phage with a broad host
range among salmonellae, which represents an added value in
phage therapy. This phage can thus be used in the creation of
a small library of phages able to act as biocontrol agents in
salmonellosis. Phage phi PVP-SE1 presents a broad lytic spec-
trum, one even broader than that of Salmonella-specific phage
Felix-O1. The most important characteristic of this phage was
the ability to lyse and consequently be produced in nonpatho-
genic E. coli, and mainly without modification of its lytic spec-
trum, in this way ensuring its stability when used in phage
therapy. Furthermore, the use of this nonpathogenic E. coli
strain in phi PVP-SE1 production will surely facilitate the
production and purification processes by eliminating the risk of
introducing a phage-resistant pathogenic bacterium. The con-
sequent cost reduction and increased safety of the phage prep-
arations will lead to easier and faster approval for commercial
applications.
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